Lytix Biopharma reported final Phase II data for ruxotemitide (LTX-315) combined with pembrolizumab in checkpoint inhibitor-refractory advanced melanoma, showing a 13.6% objective response rate and a 40.9% clinical benefit rate in a heavily pretreated population — results that, while modest in absolute terms, include durable responses extending beyond 24 months in a setting where few approved options exist.
ATLAS-IT-05 (NCT04796194) is an open-label, single-arm Phase II trial that enrolled patients with unresectable stage IIIB to IV metastatic melanoma whose tumors were accessible for intratumoral injection and who had progressed on prior anti-PD-1 or anti-PD-L1 therapy.
Among 22 evaluable patients, the overall response rate (ORR) was 13.6% and the clinical benefit rate — incorporating stable disease — reached 40.9%. Median progression-free survival was 6.3 months, and responding patients maintained responses beyond the 24-month analysis cutoff. The safety profile was dominated by injection-site reactions (95.7%), with fatigue, pruritus, hypotension, and anemia each occurring in roughly 21–30% of patients. No treatment-emergent adverse events led to pembrolizumab discontinuation.
The context for these numbers is significant. More than half of enrolled patients (52.1%) had received three or more prior lines of therapy, and all had prior immunotherapy exposure — a population in which even disease stabilization is difficult to achieve. The absence of a control arm limits interpretation, and the evaluable cohort of 22 patients constrains statistical precision. Cross-trial comparisons are limited by differences in patient selection, prior treatment history, and response assessment methods.
Ruxotemitide is a synthetic oncolytic peptide designed to disrupt tumor cell membranes on direct intratumoral injection, releasing tumor antigens and danger-associated molecular signals that may prime systemic antitumor immune responses. The proposed mechanism — converting immunologically cold tumors into ones capable of responding to checkpoint blockade — is the conceptual basis for combining it with pembrolizumab in patients who have already failed PD-1 inhibition. Unlike talimogene laherparepvec (Imlygic), the only FDA-approved intratumoral oncolytic agent, ruxotemitide is a non-viral synthetic peptide, which simplifies manufacturing and removes the viral safety considerations associated with live vector platforms. Cross-trial comparisons between the two are limited, but T-VEC's approval covers unresectable melanoma broadly rather than the post-checkpoint-failure niche specifically.